GSK establishes APVC fund to invest in the field of bio electronic medicine

Source: on August 9, 2013, GlaxoSmithKline announced the establishment of APVC Fund (action potential venture capital), a new $50 million strategic venture fund, which will invest in the pioneers in the field of bio electronic medicine and technology The fund's first investment was California based setpoint medical, which is believed to be a pioneer in creating implantable devices to treat inflammatory diseases The fund will complement GSK's bioelectronics R & D unit The unit was established in 2012 by GSK after two years of efforts to identify and hire the most promising researchers in this emerging field The fund's name comes from an electrical signal called action potentials that is passed along the body's neural network The irregularity or mode change of these electrical signals may be related to a wide range of diseases GSK believes that miniaturized devices or bioelectronics can be designed to read these patterns These devices can be designed to interface the peripheral nervous system with specific organs to read, change or generate electronic pulses, which can help treat various inflammatory bowel diseases, rheumatoid arthritis, respiratory diseases, metabolic diseases, including type 2 diabetes At present, the field of bio electronic medicine is still in a very early stage In collaboration with global scientists, GSK's ambition is to submit the first regulatory applications for bioelectropharmaceuticals that can interpret the human body's electronic language by 2020